文献速递哮喘

三药联合治疗未控制哮喘:III期研究网络Meta分析

Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies.
PubMed 文献 · Eur Respir J · 2021-09-02

该网络Meta分析纳入9535例未控制哮喘患者,评估ICS/LABA/LAMA固定剂量组合的疗效。结果显示含高剂量ICS的三联疗法在减少中重度急性发作和改善FEV1方面优于中剂量三联及ICS/LABA二联,且安全性无虞。

要点

  • 高剂量ICS三联疗法减少中重度急性发作优于中剂量三联及二联。
  • 高剂量ICS三联疗法预防重度急性发作优于中剂量三联。
  • 三联疗法对哮喘控制等效且无安全性担忧。

核心结论

  • ICS/LABA/LAMA固定剂量组合在未控制哮喘中有效且安全。
  • ICS剂量是治疗有中重度急性发作史患者的关键区分因素。

研究设计与样本

  • III期随机对照试验的网络Meta分析,共纳入9535例未控制哮喘患者。

主要发现

  • 高剂量ICS三联疗法相比中剂量ICS/LABA/LAMA固定剂量组合及中高剂量ICS/LABA固定剂量组合,降低中重度急性发作的相对风险为0.61-0.80(p<0.05)。
  • 高剂量ICS三联疗法使谷值FEV1增加33至114 mL(p<0.05)。
  • 高剂量ICS三联疗法预防重度急性发作优于中剂量ICS/LABA/LAMA固定剂量组合,相对风险0.46-0.65(p<0.05),但对中度急性发作无显著差异(p>0.05)。
  • 三联疗法在哮喘控制方面效果相当,无安全性担忧。

临床怎么用

  • 对于有中重度急性发作史的未控制哮喘患者,可考虑含高剂量ICS的ICS/LABA/LAMA三联疗法。
  • 选择三联疗法时,ICS剂量是决策的关键因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Conflicting evidence is currently available concerning the impact on asthma exacerbation of triple inhaled corticosteroid (ICS)/long-acting β2-adrenoceptor agonist (LABA)/long-acting muscarinic receptor antagonist (LAMA) fixed-dose combination (FDC).Since meta-analyses allow settling controversies of apparently inconsistent results, we performed a network meta-analysis of phase III randomised controlled trials including 9535 patients to assess the effect of ICS/LABA/LAMA combinations in uncontrolled asthma.Triple combination therapies with an ICS administered at high dose (HD) were more effective (p<0.05) than medium-dose (MD) ICS/LABA/LAMA FDC and both MD and HD ICS/LABA FDCs against moderate to severe exacerbation (relative risk 0.61-0.80) and increasing trough forced expiratory volume in 1 s (from +33 to +114 mL). Triple combination therapies including HD ICS were superior (p<0.05) to MD ICS/LABA/LAMA FDC in preventing severe exacerbation (relative risk 0.46-0.65), but not with respect to moderate exacerbation (p>0.05). Triple combination therapies were equally effective on asthma control, with no safety concerns.This quantitative synthesis suggests that ICS/LABA/LAMA FDCs are effective and safe in uncontrolled asthma, and that the dose of ICS in the combination represents the discriminating factor to treat patients with a history of moderate or severe exacerbation.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Rogliani P, Ritondo BL, Calzetta L, et al. Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. Eur Respir J. 2021. PMID: 33509960. doi:10.1183/13993003.04233-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。